Vital Therapies (VTL) Announces Third Quarter Financial Results
11/4/2016 8:17:49 AM
SAN DIEGO, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced results for the third quarter ended September 30, 2016.
Key Recent Developments
- Twenty subjects have been enrolled at sites in the United States and Europe in VTL-308, the Company’s phase 3 randomized, controlled, open-label trial, designed to evaluate the ELAD System in subjects with severe acute alcoholic hepatitis (sAAH). There are now 33 sites open for enrollment in VTL-308.
comments powered by